about
Progression of structural neuropathology in preclinical Huntington's disease: a tensor based morphometry study.STroke imAging pRevention and treatment (START): A longitudinal stroke cohort study: Clinical trials protocol.A unifying explanation of primary generalized seizures through nonlinear brain modeling and bifurcation analysis.Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson's disease.Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients.A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND).Focal myoclonus-dystonia of the leg secondary to a lesion of the posterolateral putamen: clinical and neurophysiological features.The relationship between cortical and spinal hyperexcitability and clinical disease severity in stiff-man syndrome.Movement disorders associated with CLIPPERS.Cortical limb myoclonus in pathologically proven progressive supranuclear palsy.Treatment of proximal upper limb tremor with botulinum toxin therapy.The spot sign and tranexamic acid on preventing ICH growth--AUStralasia Trial (STOP-AUST): protocol of a phase II randomized, placebo-controlled, double-blind, multicenter trial.The Toronto Western Spasmodic Torticollis Rating Scale: reliability in neurologists and physiotherapists.24 h Levodopa-carbidopa intestinal gel may reduce falls and "unresponsive" freezing of gait in Parkinson's disease.Dysexecutive behaviour following deep brain lesions--a different type of disconnection syndrome?Active exercise for individuals with cervical dystonia: a pilot randomized controlled trialAbnormalities of neuromuscular transmission in patients with Miller-Fisher syndromeDramatic improvement of truncal tardive dystonia following globus pallidus pars interna deep brain stimulationA survey of falls in people with dystoniaLevodopa/carbidopa intestinal gel infusion can improve camptocormia in Parkinson's disease
P50
Q35487438-86A5D9B1-D7C4-46DE-B1B8-44B6EEC68885Q45923718-A69CBBD0-F7A2-4D0F-B820-C06ABA4BC527Q46798790-D2836E3E-8147-45C0-ACF1-A289578DC8E7Q47853875-59DD190E-6FFE-406F-BEC1-F6440100D190Q48169010-1EBCCBCF-E5CC-42E6-ABB4-1A8A3A4D920EQ48268410-DED0B80F-3FE1-4A32-AF4F-CD7843D5B2ECQ48346981-E373E53B-E758-448E-9B5A-ED475FC76DE0Q48516969-0850AEE5-4569-427B-930F-8D86169E009FQ48876106-2F0C446C-AB5A-4F03-AB67-2C17B9E9A0BDQ48934426-195436BB-678C-41A1-94C0-798702BD4AF1Q50248253-D2C19774-AE93-415B-8493-34EEDE599DEAQ50694058-FBA0FE8F-2718-4C1B-B562-631A2F91438CQ53096937-746A2E54-075A-4421-984D-88E6C567ABAEQ53640521-B154BFC8-A581-4353-8F16-C943ECF7257FQ84045400-29A6E00D-8FAB-4AFA-BDC0-E7777802FA7DQ84824435-53AE3710-5C8C-4502-9518-99ACA741A74AQ84913965-BBA0BC58-5190-4339-AE0E-4D61CE9A7DF5Q86988347-2AB214D7-74B4-45C1-9AD8-39BE35F5C98EQ91720235-791C51FA-6A9B-4CD6-BB21-A42D10B6D8DFQ92915043-F849F8FB-4969-4454-9C5D-BB4EA27F3E01
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Neil Mahant
@ast
Neil Mahant
@en
Neil Mahant
@es
Neil Mahant
@nl
Neil Mahant
@sl
type
label
Neil Mahant
@ast
Neil Mahant
@en
Neil Mahant
@es
Neil Mahant
@nl
Neil Mahant
@sl
prefLabel
Neil Mahant
@ast
Neil Mahant
@en
Neil Mahant
@es
Neil Mahant
@nl
Neil Mahant
@sl
P106
P1153
8908686800
P21
P31
P496
0000-0003-0527-3932